Source: BioSpace

Schrodinger: Schrdinger Announces Closing of Public Offering - Aug 17, 2020

Schrödinger, Inc., whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, announced the closing of its underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $66.00 per share.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Ramy Farid's photo - President & CEO of Schrodinger

President & CEO

Ramy Farid

CEO Approval Rating


Schrodinger develops a chemical simulation software that offers drug design and molecular modeling solutions for pharmaceutical and biotechnology companies. Read more